Avraham Eisbruch MD

Dr. Eisbruch has led many investigations and published over 200 peer-reviewed papers involving chemo-irradiation combinations for head and neck cancer and the characteristics of the toxicity of therapy. He has also investigated and developed methods to reduce toxicity using physiologic and metabolic imaging in treatment planning, prognosis, and therapy assessment, and assessing the uncertainties related to and value of therapy adaptation. He was the principal investigator of the first RTOG IMRT study, 00-22.

Dr. Eisbruch's most recent research includes using functional MRI to guide RT intensification for poor prognosis head and neck patients, funded by the NIH.